
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition Inc., a biopharmaceutical firm focusing on neurodegenerative disease treatments, particularly Alzheimer's, is expected to see significant sales growth as their contracting strategies are implemented, with substantial acceleration anticipated in 2026. The company's proactive approach includes building a dedicated commercial team to differentiate ZUNVEYL from existing treatments and explore additional licensing opportunities. Furthermore, with an expected year-end 2025 cash balance of approximately $63 million, Alpha Cognition appears well-positioned to sustain operations and reach profitability in the near to medium term.
Bears say
Alpha Cognition's full-year 2025 net sales forecast has been reduced to $5.7 million from a previous estimate of $11.7 million, reflecting expectations of slower contracting and reimbursement processes. Key risks for the company include potential delays in the launch of its lead product, ZUNVEYL, as well as challenges related to market uptake due to pricing pressures and increased competition from both generic and branded drugs. Additionally, there are concerns about possible setbacks in clinical development and the risk of medium- to long-term dilution, which contributes to an overall negative outlook for the stock.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares